Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
April 10 2024 - 7:00AM
Business Wire
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, today
announced that, for the second year in a row, its chief financial
officer, Frank Stokes, has been selected as a Top 25 CFO of Houston
by TOP CFOs (formerly Finance & Investing). The annual award
recognizes the top-performing CFOs by region, selected for their
skills in leading complex financial departments and their ability
to drive growth and profitability as influential financial leaders
in their communities.
“I am proud of Frank for earning a second placement among
Houston’s Top 25 CFOs,” said Derek Maetzold, president and chief
executive officer at Castle Biosciences. “In a city as dynamic and
competitive as Houston, this recognition is a testament to Frank’s
financial leadership in the growth and development of our
company.”
Stokes has served as Castle’s chief financial officer since
December 2017. Stokes holds a B.S. degree in business
administration and J.D. and MBA degrees from the University of
North Carolina at Chapel Hill.
The comprehensive list of the Top 25 CFOs of Houston for 2024
can be viewed here.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics
company improving health through innovative tests that guide
patient care. The Company aims to transform disease management by
keeping people first: patients, clinicians, employees and
investors.
Castle’s current portfolio consists of tests for skin cancers,
Barrett’s esophagus, mental health conditions and uveal melanoma.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to help guide systemic therapy
selection for patients with moderate-to-severe atopic dermatitis,
psoriasis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM,
DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle
Biosciences, Inc.
About TOP CFOs
TOP CFOs (formerly Finance & Investing) is a comprehensive
source for research and information, business news, and corporate
actions related to banking, finance, public and private markets,
and other topics relevant to CFOs. Based in New York City, the firm
is run by a seasoned team of editors, writers and media
professionals highly knowledgeable on finance and capital
markets.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240410056539/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com Media Contact: Allison
Marshall amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Jul 2023 to Jul 2024